After 50 years of research...
Digital Desk: A new treatment, after 50 years of progress, for patients afflicted with asthma and COPD has been found, offering new hope for many sick patients. It was concluded that Benralizumab, which is classically prescribed for patients who have severe asthma, resulted in better flare prevention and control when compared with conventional steroid tablets.
A Phase 2 ABRA trial with encouraging results was completed at King's College London in collaboration with the University of Oxford. The study determined that, compared with drugs, a dose of Benralizumab, when administered during a flare-up of asthma or COPD, enormously suppresses lung inflammation.
It is the potential replacement of steroids, which often have undesirable side effects, that is being conveyed as a significant advance in respiratory therapy. Medical professionals call this breakthrough a "game-changer" and push for increased funding for lung health research to further improve therapies for millions worldwide. This new strategy can benefit asthma and COPD patients, giving them a safer and more efficient way of managing their conditions.
